Pharmacotherapy for metabolic and cellular stress in degenerative retinal diseases.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
24
06
2019
revised:
08
11
2019
accepted:
26
11
2019
pubmed:
7
12
2019
medline:
1
5
2021
entrez:
7
12
2019
Statut:
ppublish
Résumé
Retinal photoreceptors continually endure stresses associated with prolonged light exposure and the metabolic demands of dark adaptation. Although healthy photoreceptors are able to withstand these stresses for several decades, the disease-affected retina functions at a reduced capacity and is at an increased risk for dysfunction. To alleviate cellular and metabolic stressors in degenerative retinal diseases, a new class of drugs that modulate the metabolic activity of the retina have been developed. A clinical candidate in this class (emixustat) has been shown to reduce retinal pathology in various animal models of human retinal disease and is currently under clinical study. Here, we describe the pharmacological properties of emixustat, its mechanisms of action, and potential for use in the treatment of specific retinal diseases.
Identifiants
pubmed: 31809750
pii: S1359-6446(19)30455-6
doi: 10.1016/j.drudis.2019.11.013
pii:
doi:
Substances chimiques
Phenyl Ethers
0
Propanolamines
0
emixustat
02DZ1HBF0M
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
292-304Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.